We'd be surprised if Pacific Biosciences of California, Inc. (NASDAQ:PACB) shareholders haven't noticed that the President, Christian O. Henry, recently sold US$481k worth of stock at US$5.94 per share. That sale was 22% of their holding, so it does make us raise an eyebrow.
View our latest analysis for Pacific Biosciences of California
The Last 12 Months Of Insider Transactions At Pacific Biosciences of California
In fact, the recent sale by President Christian O. Henry was not their only sale of Pacific Biosciences of California shares this year. Earlier in the year, they fetched US$10.12 per share in a -US$980k sale. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$5.11. So it may not shed much light on insider confidence at current levels.
Pacific Biosciences of California insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Pacific Biosciences of California
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Based on our data, Pacific Biosciences of California insiders have about 0.3% of the stock, worth approximately US$4.2m. We consider this fairly low insider ownership.
So What Does This Data Suggest About Pacific Biosciences of California Insiders?
Insiders sold Pacific Biosciences of California shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Pacific Biosciences of California. To assist with this, we've discovered 4 warning signs that you should run your eye over to get a better picture of Pacific Biosciences of California.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we're here to simplify it.
Discover if Pacific Biosciences of California might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
This article has been translated from its original English version, which you can find here.